Phoma (dlbcl) by whole-exome sequencing. Proc Natl Acad Sci Usa. 2012;109(10):3879?four. doi

Phoma (dlbcl) by whole-exome sequencing. Proc Natl Acad Sci United states of america. 2012;109(ten):3879?four. doi:ten.1073/pnas.1121343109.29. Chindelevitch L, Ziemek D, Enayetallah A, Randhawa R, Sidders B, Brockel C, et al. Causal reasoning on organic networks: interpreting transcriptional modifications. Bioinformatics. 2012;28(eight):1114?one. doi:10.1093/bioinformatics/bts090. thirty. Chindelevitch L, Loh P-R, Enayetallah A, Berger B, Ziemek D. Assessing statistical importance in causal graphs. BMC Bioinf. 2012;13:35. doi:10.1186/1471-2105-13-35. 31. Espinosa AM, Alfaro A, Roman-Basaure E, Guardado-Estrada M, ela P, Serralde C, et al. Mitosis is actually a supply of probable markers for screening and survival and therapeutic targets in cervical cancer. PLoS 1. 2013;8(two): 55975. doi:10.1371/journal.pone.0055975. 32. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Encequidar et al. Involvement of upregulation of depdc1 (dep domain that contains one) in bladder carcinogenesis. Oncogene. 2007;26(44):6448?5. doi:10.1038/sj.onc.1210466. 33. Kassambara A, PubMed ID: Schoenhals M, Moreaux J, Veyrune J-L, Reme T, Goldschmidt H, et al. Inhibition of DEPDC1A, a bad prognostic marker in several myeloma, delays progress and induces mature plasma mobile markers in malignant plasma cells. PLoS A single. 2013;eight(four):62752. doi:ten.1371/journal.pone.0062752. 34. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463?sixteen. doi:ten.1146/ 35. Teshima J, Doi H, Fujimori K, Watanabe M, Nakajima N, Nakano T, et al. A human thyroid cancer mobile line, dh-14-3, newly proven from badly differentiated thyroid carcinoma. Tohoku J Exp Med. 2013;230(2):75?two. 36. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491?. 37. DeClerck YA. Interactions amongst tumour cells and stromal cells and proteolytic modification on the extracellular matrix by metalloproteinases in cancer. Eur J Cancer. 2000;36(ten):1258?8. 38. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic mobile demise of most cancers PubMed ID: mobile traces by overexpression of timp-3. Br J Most cancers. 1999;seventy nine(9-10):1347?five. doi:ten.1038/sj.bjc.6690217. 39. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, et al. Timp-2 over-expression lowers invasion and angiogenesis and safeguards b16f10 melanoma cells from apoptosis. Int J Cancer. 1998;seventy five(2):246?three. forty. Iruela-Arispe ML, Carpizo D, Luque A. Adamts1: a matrix metalloprotease with angioinhibitory homes. Ann N Y Acad Sci. 2003;995:183?0. 41. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The membrane-anchored mmp inhibitor reck can be a important regulator of extracellular matrix integrity and angiogenesis. Cell. 2001;107(6):789?00. 42. Weber GF, Lett GS, Haubein NC. Osteopontin can be a marker for cancer aggressiveness and client survival. Br J Most cancers. 2010;103(six):861?. doi:10.1038/sj.bjc.6605834. 43. Briese J, Cheng S, Ezzat S, Liu W, Winer D, Wagener C, et al. Osteopontin (opn) expression in thyroid carcinoma. Anticancer Res. 2010;thirty(five):1681?. 44. Oler G, Camacho CP, Hojaij FC, Michaluart P, Riggins GJ, Cerutti JM. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with braf mutational standing and lymph node metastasis. Clin Cancer Res. 2008;fourteen(15):4735?2. doi:ten.1158/1078-0432.CCR-07-4372. 45. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, Falco VD, et al. Osteopontin is overexpressed in human papilla.